Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News NanoViricides Inc NNVC

Healthcare Biotechnology
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:NNVC)

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

ACCESS Newswire 9 days ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

ACCESS Newswire December 1, 2025

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

ACCESS Newswire November 17, 2025

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

ACCESS Newswire November 14, 2025

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

ACCESS Newswire November 12, 2025

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

ACCESS Newswire November 11, 2025

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

ACCESS Newswire November 10, 2025

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

ACCESS Newswire November 5, 2025

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

ACCESS Newswire November 3, 2025
View More News ››

Opinion & Analysis (NYSEAM:NNVC)

Micro cap biotech is nano-fighting the swine flu

AllPennyStocks.com April 29, 2009
View More Opinion ››

Bullboard Posts (NYSEAM:NNVC)

A future powerhouse in biotech, $NNVC is ready to thrive!

NanoViricides, Inc. (NNVC) is making waves in the biotechnology sector, particularly in the rapidly expanding field of nanomedicine...
lelianicruz - December 4, 2024

NanoViricides’ Financial Position Supports Research Goals

NanoViricides, Inc. (NYSE: $NNVC), a clinical-stage company specializing in innovative nanomaterials for antiviral therapy, is making...
jacksolle77 - December 3, 2024

NanoViricides (NNVC): Positioned for Significant Growth

  NanoViricides, Inc. (NNVC), a leader in nanomedicine-based antiviral therapies, is poised for remarkable growth in the...
khandaanita4444 - December 3, 2024

NanoViricides'($NNVC) Impact on Global Healthcare

NanoViricides, Inc. is a cutting-edge clinical-stage biotechnology company that is revolutionizing the field of antiviral therapeutics....
lelianicruz - December 3, 2024

Revolutionizing Antiviral Medicine with NV-387:$NNVC

NanoViricides, Inc., a clinical-stage biotech leader, is transforming antiviral treatment through its innovative nanomedicine platform....
khandaanita4444 - November 29, 2024

$NNVC: Pioneering the Future of Antiviral Therapies

NanoViricides, Inc., a clinical-stage biotechnology company, is transforming the landscape of antiviral medicine with its proprietary...
lelianicruz - November 29, 2024
View more Bullboard ››

NU E Power Corp

NU E Power Corp

NU E Power Corp. develops, owns, and operates renewable energy projects in Canada. It is involved in the development of solar ...
View More »

Podcasts